1. Home
  2. XNET vs REPL Comparison

XNET vs REPL Comparison

Compare XNET & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

N/A

Current Price

$4.96

Market Cap

358.4M

Sector

Technology

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$9.96

Market Cap

407.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XNET
REPL
Founded
2003
2015
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
358.4M
407.1M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
XNET
REPL
Price
$4.96
$9.96
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
236.3K
8.0M
Earning Date
05-14-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.02
$1.50
52 Week High
$11.03
$13.24

Technical Indicators

Market Signals
Indicator
XNET
REPL
Relative Strength Index (RSI) 33.53 77.88
Support Level N/A $9.50
Resistance Level $6.12 $10.67
Average True Range (ATR) 0.30 0.66
MACD -0.08 0.60
Stochastic Oscillator 0.85 90.83

Price Performance

Historical Comparison
XNET
REPL

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: